Related Experiment Video

Updated: May 20, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Immunotherapy for polyomaviruses: opportunities and challenges

Tina Dalianis1

  • 1Department of Oncology-Pathology, Karolinska Institute, Cancer Center Karolinska, Karolinska University Hospital, SE-171 76 Stockholm, Sweden. tina.dalianis@ki.se

Immunotherapy
|July 14, 2012
PubMed

Insights

Human polyomaviruses (HPyVs) are common but usually harmless. This review discusses HPyV-associated diseases in immunosuppressed individuals and explores VP1 virus-like particles as potential vaccines.

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Polyomaviruses are ubiquitous DNA viruses found in mammals and birds.
  • The first human polyomaviruses (HPyVs), BK virus and JC virus, were discovered in 1971.
  • Since 2007, seven new HPyVs have been identified, increasing our understanding of their prevalence and impact.

Purpose of the Study:

  • To review the diseases caused by polyomaviruses, particularly in immunosuppressed individuals.
  • To explore the potential of using the viral capsid protein VP1 to create virus-like particles (VLPs) for vaccine development against HPyV infections.

Main Methods:

  • Literature review of polyomavirus research.
  • Analysis of clinical associations between HPyVs and diseases.
  • Evaluation of VP1 protein's potential for VLP formation and vaccine applications.

Main Results:

  • Merkel cell polyomavirus is linked to Merkel cell carcinoma, predominantly in elderly and immunocompromised individuals.
  • Trichodyplasia spinulosa polyomavirus is associated with a skin disorder in immunosuppressed patients.
  • Many HPyVs cause significant health issues in individuals with weakened immune systems.

Conclusions:

  • Polyomaviruses pose a threat to immunosuppressed populations, causing various diseases.
  • The VP1 protein shows promise for developing effective virus-like particle vaccines against polyomavirus infections.

More Related Videos

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...